1stOncology™: Cancer Intelligence Service – Page 12625 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Incyte to Present at Upcoming Investor Conference

On November 14, 2019 Incyte Corporation (Nasdaq:INCY) reported that it will present at the Piper Jaffray 31st Annual Healthcare Conference on Wednesday, December 4, 2019 at 8:30 am (EST) in New York (Press release, Incyte, NOV 14, 2019, View Source [SID1234551241]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

The presentation will be webcast live and can be accessed at www.incyte.com under For Investors, Events and Presentations and will be available for replay for 30 days. Investors interested in listening to the live webcast should log on before the start time in order to download any software required.

DelMar Pharmaceuticals Announces Fiscal First Quarter 2020 Financial Results and Recent Corporate Updates

On November 14, 2019 DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new cancer therapies, reported its financial results for the quarter ended September 30, 2019 (Press release, DelMar Pharmaceuticals, NOV 14, 2019, https://ir.delmarpharma.com/news/detail/919/delmar-pharmaceuticals-announces-fiscal-first-quarter-2020-financial-results-and-recent-corporate-updates [SID1234551240]).

"Following a productive quarter, we continue to believe that our cash position will provide the runway to enable us to achieve topline results for two of our three patient groups in our two Phase 2 trials. We are seeing encouraging progress and look forward to sharing our upcoming update of data from two poster presentations at the Society for Neuro-Oncology Annual Meeting," commented Saiid Zarrabian, DelMar’s President and Chief Executive Officer. "In the meantime, our relocation to San Diego offers the unique opportunity to access additional professionals to help advance our programs at the appropriate time. We look forward to providing updates to all of our programs soon."

RECENT CORPORATE UPDATES

November 2019 – Announced Key Opinion Leader GBM summit at the Society for Neuro-Oncology annual meeting November 22, 2019. This event will include four members of DelMar’s recently appointed Scientific Advisory Board
September 2019 – Moved corporate headquarters to San Diego, California
August 2019 – Closed an underwritten public offering with net proceeds of approximately $6.6 million
August 2019 – Provided update on Phase 2 clinical study on first line therapy in newly-diagnosed, MGMT-unmethylated GBM patients being conducted at Sun Yat-sen University Cancer Center. At the time of the update, nine patients were assessed as having achieved complete response, seven were assessed with stable disease, and one was assessed with disease progression
July 2019 – Enrolled first patient in adjuvant (pre-temozolomide maintenance) arm of Phase 2 open label study of VAL-083 being conducted at MD Anderson Cancer Center (MDACC)
July 2019 – Provided enrollment update of Phase 2 open label study of VAL-083 in recurrent GBM patients with MGMT-unmethylated status. As of this announcement, 56 of the planned 83 patients had been enrolled in the recurrent arm of the study being conducted at MDACC
SUMMARY OF FINANCIAL RESULTS FOR FISCAL QUARTER ENDED SEPTEMBER 30, 2019

At September 30, 2019, the Company had cash and cash equivalents on hand of approximately $8.1 million. In August 2019, the Company completed an underwritten public offering for net proceeds of approximately $6.6 million. The proceeds from the August 2019 financing combined with cash and cash equivalents on hand at June 30, 2019 are expected to be sufficient to fund the Company’s planned operations into the fourth quarter of calendar year 2020.

For the quarter ended September 30, 2019, the Company reported a net loss of approximately $1.6 million, or $0.21 per share, compared to a net loss of approximately $2.0 million, or $0.88 per share, for the same period of 2018.

DelMar’s financial statements as filed with the U.S. Securities Exchange Commission can be viewed on the Company’s website at: View Source

Evotec to attend upcoming investor conferences

On November 14, 2019 Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) reported that its management will be presenting at and attending the following upcoming conferences in November and December 2019 (Press release, Evotec, NOV 14, 2019, View Source;announcements/press-releases/p/evotec-to-attend-upcoming-investor-conferences-5869 [SID1234551239]):

Jefferies London Healthcare Conference, London, UK

Date: Wednesday, 20 November 2019
Presentation: 20 November 2019, 8.00 am (GMT)
Venue: London, UK
Attendee: Enno Spillner, Chief Financial Officer

LBBW German Company Day, London, UK

Date: Thursday, 21 November 2019
Venue: London, UK
Attendee: Enno Spillner, Chief Financial Officer

German Equity Forum, Frankfurt, Germany

Date: Monday, 25 November 2019
Presentation: 25 November 2019, 11.30 am (CET)
Venue: Frankfurt am Main, Germany
Attendee: Dr Werner Lanthaler, Chief Executive Officer

Kempen’s London Conference, London, UK

Date: Wednesday, 27 November 2019
Venue: London, UK
Attendee: Dr Werner Lanthaler, Chief Executive Officer

Berenberg European Corporate Conference, Surrey, UK

Date: Tuesday, 03 December 2019
Presentation: 03 December 2019, 11.00 am (GMT)
Venue: Surrey, UK
Attendee: Enno Spillner, Chief Financial Officer

BioCryst Prices Public Offering of Common Stock

On November 14, 2019 BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) reported the pricing of an underwritten public offering of 37,931,035 shares of its common stock, offered at a price to the public of $1.45 per share (Press release, BioCryst Pharmaceuticals, NOV 14, 2019, View Source [SID1234551158]). The gross proceeds from this offering to BioCryst are expected to be $55 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by BioCryst.

BioCryst has granted the underwriters a 30-day option to purchase up to an additional 5,689,655 shares of its common stock. The offering is expected to close on or about November 18, 2019, subject to customary closing conditions. BioCryst expects to use the net proceeds of this offering for general corporate purposes, which may include, but are not limited to, worldwide development, manufacturing, regulatory and commercial activities for the prophylactic BCX7353 program, primarily focusing on the U.S., EU and Japan; development of the BCX9930 program; development of the BCX9250 program; post-approval commitments for RAPIVAB/ALPIVAB; funding clinical development of pipeline assets; and capital expenditures and other general corporate expenses.

J.P. Morgan is acting as sole book-running manager for the offering. JMP Securities and H.C. Wainwright & Co. are acting as lead managers for the offering.

A shelf registration statement on Form S-3 relating to the shares of common stock described above has been previously filed with and declared effective by the U.S. Securities and Exchange Commission ("SEC"). This press release does not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted.

This offering is being made by means of a prospectus supplement and related prospectus. A preliminary prospectus supplement relating to the offering has been filed with the SEC and is available on its website at www.sec.gov. Copies of the final prospectus supplement, when available, and accompanying prospectus may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by telephone: 1-866-803-9204.

Theragnostics strengthens leadership team with two key appointments

On November 14, 2019 Theragnostics, which is developing molecular radiotherapy for imaging and treating a broad range of cancers, reported two strategic hires to its leadership team with the appointment of Dr Daniel Stevens as Chief Medical Officer (CMO) and Chris Stirling to the Board as Non-Executive Director (Press release, Theragnostics, NOV 14, 2019, View Source [SID1234551133]).

Chris Sterling has extensive experience in the life sciences industry advising multinational companies such as GlaxoSmithKline and Syngenta (Novartis/AstraZeneca) in cross-border acquisitions, mergers and disposals. He was previously Chairman of KPMG’s Global Life Sciences sector where he built the practice in markets across the world including China, India and Brazil as well as the established markets in North America, Europe and Japan. He has held many leadership positions and senior client facing roles at KPMG both as an Audit and Transaction Services partner. Chris is an FCA Chartered Accountant and holds a Master’s in Engineering Science from the University of Oxford.

Recently appointed CMO Dr Daniel Stevens has a successful track record in US and EU radiopharmaceutical registrations and has led development teams through Phase 1 to Phase 3 of novel radiopharmaceutical therapies. Daniel is a UK trained physician with a broad frontline clinical experience including five years working as both an academic and a clinician, and a specialist period undertaking basic cancer research at the University of Oxford.

Commenting on the news, Nick Stevens, Executive Chairman of Theragnostics, said:
"As we continue to grow, it is important to be able to attract high calibre individuals who have the global experience to help Theragnostics on its journey. Chris’ business acumen, extensive experience and exemplary track record in striking deals with large players in the sector will be invaluable in implementing our strategy of bringing novel diagnostic agents and new targeted therapies to patients."

Greg Mullen, Chief Executive Officer of Theragnostics, added:
"I’m very pleased to have someone of Dan’s expertise and track record join our team. This appointment comes at a pivotal moment when we prepare for the next stage of growth as a company and complements the management team as we advance our programmes into clinical development."

Theragnostics’ technology platform enables the development of molecular radiotherapy based on a PARPi for imaging and treating cancer. Theragnostics modifies a PARPi drug molecule with a radioactive atom to create a radionuclide PARPi (rPARPi). This can either be used to image PARP in a cancer patient for diagnostic use or the radioactive isotope can be used to deliver a therapeutic dose of radiation into tumour cells, which offers the potential to molecularly target the radiation in order to hit and kill tumour cells whilst avoiding damage to healthy cells and associated side effects.